Nomoto, H., Kito, K., Iesaka, H., Handa, T., Yanagiya, S., Miya, A., . . . Atsumi, T. (2023, October). Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage. Diabetology & Metabolic Syndrome.
Chicagoスタイル(17版)引用形式Nomoto, Hiroshi, et al. "Preferable Effects of Pemafibrate on Liver Function and Fibrosis in Subjects with Type 2 Diabetes Complicated with Liver Damage." Diabetology & Metabolic Syndrome Oct. 2023.
MLA(9版)引用形式Nomoto, Hiroshi, et al. "Preferable Effects of Pemafibrate on Liver Function and Fibrosis in Subjects with Type 2 Diabetes Complicated with Liver Damage." Diabetology & Metabolic Syndrome, Oct. 2023.
警告: この引用は必ずしも正確ではありません.